S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
These are the Top 4 Stocks for Buybacks in 2024
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
These are the Top 4 Stocks for Buybacks in 2024
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
These are the Top 4 Stocks for Buybacks in 2024
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
These are the Top 4 Stocks for Buybacks in 2024
NASDAQ:ALNA

Allena Pharmaceuticals (ALNA) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
$0.02
$0.16
52-Week Range
N/A
Volume
96,558 shs
Average Volume
15.69 million shs
Market Capitalization
$37,000.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ALNA stock logo

About Allena Pharmaceuticals Stock (NASDAQ:ALNA)

Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.

ALNA Stock News Headlines

Allena Pharmaceuticals Inc ALNAQ Stock Quote
Allena Pharmaceuticals Inc (ALNAQ)
Now Open: Crypto emergency update
During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.
San Francisco Pharmaceuticals News
ALNA.O
Now Open: Crypto emergency update
During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.
Nano cap stock Allena surges on heavy volume
Allena Pharmaceuticals $2.8M direct offering
Why Are Allena Pharma Shares Plunging Today
Allena Pharmaceuticals, Inc. (ALNA)
Allena Pharmaceuticals, Inc.(ALNA)
See More Headlines
Receive ALNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allena Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/31/2022
Today
4/19/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:ALNA
Employees
35
Year Founded
N/A

Profitability

Net Income
$-48,660,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.23 per share

Miscellaneous

Free Float
117,566,000
Market Cap
$37,000.00
Optionable
Not Optionable
Beta
1.13
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Dr. Alexey L. Margolin Ph.D. (Age 69)
    Co-Founder & Chairman
    Comp: $70k
  • Dr. Louis Brenner M.B.A. (Age 52)
    M.D., Pres, CEO & Director
    Comp: $576.86k
  • Dr. Richard D. Katz (Age 58)
    CFO, Principal Financial Officer & Principal Accounting Officer
    Comp: $400.67k
  • Mr. Robert Gallotto (Age 57)
    Co-Founder & Strategic Adviser
  • Mr. Geoffrey A. Swire (Age 49)
    Sr. VP of Corp. Devel., Acting COO & Interim Principal Operating Officer
  • Mr. Hugh Wight
    Sr. VP of Technical Operations
  • Dr. Alicja Januszewicz Ph.D.
    VP of People & Culture
  • Dr. David J. Clark (Age 57)
    Chief Medical Officer

ALNA Stock Analysis - Frequently Asked Questions

How were Allena Pharmaceuticals' earnings last quarter?

Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) announced its quarterly earnings data on Thursday, March, 31st. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.06.

What is Louis Brenner, M.D.'s approval rating as Allena Pharmaceuticals' CEO?

1 employees have rated Allena Pharmaceuticals Chief Executive Officer Louis Brenner, M.D. on Glassdoor.com. Louis Brenner, M.D. has an approval rating of 100% among the company's employees. This puts Louis Brenner, M.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Allena Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Allena Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), VYNE Therapeutics (VYNE), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), TherapeuticsMD (TXMD), VBI Vaccines (VBIV), Acasti Pharma (ACST) and Miragen Therapeutics (MGEN).

When did Allena Pharmaceuticals IPO?

Allena Pharmaceuticals (ALNA) raised $80 million in an initial public offering on Thursday, November 2nd 2017. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. Credit Suisse, Jefferies and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

This page (NASDAQ:ALNA) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners